1. Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study
- Author
-
Stéphane Schück, Philippe Serrier, Déborah Poirier, Eric Van Ganse, Nathalie Texier, Bruno Housset, Céline Pribil, Isabelle Boucot, and Nicolas Roche
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Population ,Population-based ,Prescription ,Pulmonary Disease, Chronic Obstructive ,Internal medicine ,Pulmonary Medicine ,medicine ,Humans ,COPD ,Albuterol ,Prospective Studies ,GOLD ,Practice Patterns, Physicians' ,Medical prescription ,Prospective cohort study ,education ,Intensive care medicine ,Glucocorticoids ,Pulmonologist ,Pulmonologists ,Aged ,Fluticasone-Salmeterol Drug Combination ,education.field_of_study ,Questionnaire ,business.industry ,Middle Aged ,Primary care ,medicine.disease ,Drug Utilization ,Dry-powder inhaler ,respiratory tract diseases ,Androstadienes ,Drug Combinations ,Female ,Observational study ,France ,Guideline Adherence ,business ,Research Article - Abstract
Background In Europe, administration of an inhaled corticosteroid (ICS) combined with a long-acting β2 agonist is approved in chronic obstructive pulmonary disease (COPD) patients with a pre-bronchodilator FEV1 75%) had moderate to very severe COPD. Strict compliance by prescribing physicians with the market-approved population for dry powder inhaler SFC in COPD was low, notably in ICS-naïve patients; all three conditions were fulfilled in less than a quarter of patients with prior ICS and less than 7% of ICS-naïve patients. Conclusions Prescription of dry powder inhaler SFC by GPs and pulmonologists has very low conformity with the three conditions defining the licensed COPD population. Prescription practices need to be improved and systematic FEV1 evaluation for COPD diagnosis and treatment management should be emphasized.
- Published
- 2014